xanomeline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| cholinergic agents (muscarine receptor agonists/partial antagonists used in the treatment of Alzheimer's disease) | 3652 | 131986-45-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
a cholinergic agonist; used in the treatment of Alzheimer's disease; structure given in first source
|
Drug dosage:
None
ADMET properties:
None
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D018678 | Cholinergic Agents |
| MeSH PA | D018679 | Cholinergic Agonists |
| MeSH PA | D018721 | Muscarinic Agonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D010277 | Parasympathomimetics |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D011619 | Psychotropic Drugs |
| CHEBI has role | CHEBI:35941 | serotonin agonists |
| CHEBI has role | CHEBI:38325 | muscarinic agonists |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 6.94 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| D(3) dopamine receptor | GPCR | Ki | 6.40 | PDSP | |||||
| D(2) dopamine receptor | GPCR | Ki | 6 | PDSP | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | AGONIST | Ki | 7.20 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 2A | GPCR | ANTAGONIST | Ki | 6.90 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 2B | GPCR | ANTAGONIST | Ki | 7.70 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 2C | GPCR | ANTAGONIST | Ki | 7.40 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 6 | GPCR | AGONIST | Ki | 5.90 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 7 | GPCR | AGONIST | Ki | 6.90 | IUPHAR | ||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 7.38 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 6.92 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M3 | GPCR | Ki | 7.89 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M4 | GPCR | Ki | 7.14 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M5 | GPCR | Ki | 7.10 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1B | GPCR | AGONIST | Ki | 7.30 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 1D | GPCR | AGONIST | Ki | 8.20 | IUPHAR | ||||
| Alpha-1B adrenergic receptor | GPCR | Ki | 5.80 | PDSP | |||||
| 5-hydroxytryptamine receptor 1F | GPCR | AGONIST | Ki | 6.50 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 1E | GPCR | AGONIST | Ki | 5.60 | IUPHAR | ||||
| Muscarinic acetylcholine receptor M2 | GPCR | IC50 | 7.80 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | IC50 | 8.70 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | EC50 | 5.24 | CHEMBL | |||||
| Muscarinic acetylcholine receptor | GPCR | IC50 | 8.01 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D06330 | KEGG_DRUG |
| C0246836 | UMLSCUI |
| CHEBI:10056 | CHEBI |
| XNO | PDB_CHEM_ID |
| CHEMBL21536 | ChEMBL_ID |
| DB15357 | DRUGBANK_ID |
| C075257 | MESH_SUPPLEMENTAL_RECORD_UI |
| 60809 | PUBCHEM_CID |
| 57 | IUPHAR_LIGAND_ID |
| 7125 | INN_ID |
| 152854-19-8 | SECONDARY_CAS_RN |
| 9ORI6L73CJ | UNII |
| CHEMBL2336050 | ChEMBL_ID |
Pharmaceutical products:
None